Evidence map›Paper›PMID 9450653›Full record

ArticleMolecular and cellular biochemistry1997

A role for amino acid residues in the third cytoplasmic loop in defining the ligand binding characteristics of the alpha2D-adrenergic receptor.

V Venkataraman, T Duda, R K Sharma

Erratum issuedAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

3 authors.

V VenkataramanDepartment of Cell Biology, University of Medicine and Dentistry of New Jersey, Stratford 08084, USA.
T Duda
R K Sharma

Funding

RECEPTOR CYCLASE SIGNALING NETWORKS IN RETINAR01EY010828 · NEI · UNIV OF MED/DENT NJ-SCH OSTEOPATHIC MED · PI SHARMA, RAMESHWAR K · 1994 to 2002
$1.1M
STRUCTURE AND FUNCTION OF ALPHA2-ADRENERGIC RECEPTORR01NS023744 · NINDS · UNIV OF MED/DENT NJ-SCH OSTEOPATHIC MED · PI SHARMA, RAMESHWAR K · 1987 to 1996
–
ATP REGULATION OF MEMBRANE GUANYLATE CYCLASE ACTIVITYR15HL058151 · NHLBI · UNIV OF MED/DENT NJ-SCH OSTEOPATHIC MED · PI DUDA, TERESA · 1997 to 1997
–
NEI NIH HHS EY10828NHLBI NIH HHS HL 58151NINDS NIH HHS NS 23744
6 · The paper itself

Abstract

In this report, 5 amino acid residues (aa) in the third cytoplasmic loop of the alpha 2D-adrenergic receptor are identified which (individually or together) alter its ligand-binding characteristics. An important structural discrepancy exists in the third cytoplasmic loop of the alpha 2D-ARs encoded by the rat cDNA and the rat gene--five aa are different. The newly identified bovine receptor as well as the mouse receptor contained the 5 aa identical to that encoded by the rat cDNA. Site-directed mutation of these residues to those of the rat gene encoded receptor resulted in alteration of binding characteristics: significant changes in the ability of the mutant receptor to bind to a number of agonists and antagonists were observed--ranging from a decrease by half in the case of oxymetazoline, to near total loss of binding in the case of prazosin. Thus, the mutant receptor was no longer pure alpha 2D-AR. This indicated a hitherto unrealized role of the third cytoplasmic loop in defining the ligand-binding characteristics of the receptor, and also suggested that the rat gene sequence was most probably in error.

Indexed as

Amino AcidsAmino Acid SequenceAnimalsCattleClonidineCOS CellsCytoplasmEpinephrineHumansLigandsMiceMolecular Sequence DataMutagenesis, Site-DirectedOxymetazolinePhentolaminePrazosinAmino AcidsapraclonidineClonidineEpinephrineLigandsOxymetazolinePhentolaminePrazosinReceptors, Adrenergic, alpha-2Yohimbine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.